Treatment-related AEs that led to dose reduction and treatment discontinuation of any study agent occurred in eight patients (18%; one increased ALT, one increased aspartate aminotransferase (AST), one headache, three paronychia, two rash and three dermatitis acneiform) and two patients (4%; one pneumonitis and one dermatitis), respectively. The gene discussed is GPT; the disease is pneumonitis.